Icon

LOVENOX (PRESERVATIVE FREE) (nda020164)- (30MG/0.3ML (100MG/ML),40MG/0.4ML (100MG/ML),60MG/0.6ML (100MG/ML),80MG/0.8ML (100MG/ML),90MG/0.6ML (150MG/ML),100MG/ML (100MG/ML),120MG/0.8ML (150MG/ML),150MG/ML (150MG/ML))

ENOXAPARIN SODIUM SANOFI AVENTIS US
30MG/0.3ML (100MG/ML),40MG/0.4ML (100MG/ML),60MG/0.6ML (100MG/ML),80MG/0.8ML (100MG/ML),90MG/0.6ML (150MG/ML),100MG/ML (100MG/ML),120MG/0.8ML (150MG/ML),150MG/ML (150MG/ML)
Yes No
2012-Feb-14 Expired
None None
None No
Lovenox is a low molecular weight heparin [LMWH] indicated for: • Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness • Inpatient treatment of acute DVT with or without pulmonary embolism • Outpatient treatment of acute DVT without pulmonary embolism. • Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction [MI] • Treatment of acute ST-segment elevation myocardial infarction [STEMI] managed medically or with subsequent percutaneous coronary intervention [PCI]
7 0 4
Total Other Developers None
Drugs with Suitability No
30MG/0.3ML (100MG/ML) ** ** - 3 1
40MG/0.4ML (100MG/ML) ** ** - - 4
60MG/0.6ML (100MG/ML) ** ** - - 4
80MG/0.8ML (100MG/ML) ** ** - - 4
90MG/0.6ML (150MG/ML) ** ** - - -
100MG/ML (100MG/ML) ** ** - - 7
120MG/0.8ML (150MG/ML) ** ** - - 4
150MG/ML (150MG/ML) ** ** - - 7
NDA Sales Available Total Generic Sales Available
Yes 4
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ***** ****** *********** *** *********** ***** ****** ***** ***, *****, - *****, ***** (***) ***
****** ***** ***** ****** ******* *** *********** ****** **. *** - ***, *** & ***, **** ************* ***** *****, *. *. *****, ******** ****, ******** - ************* ******, ******* - ********** ********, *********, ********* ******, ***** (***) ***
****** ***** ***** ****** ******* *********** ****** **. *** - ***, *** & ***, **** ************* ***** *****, *. *. *****, ******** ****, ******** - ************* ******, ******* - ********** ********, *********, ********* ******, ***** (***) ***
****** ******** ******* ******** ******* ************** **., ***. *********** **. **, ************* ****, ******* ********, ********, ********* ******, ***** (***) ***
****** ** ****** ********** *. ******* *********** **** **.*, **. **. ***/*, ******* ****, *****-**, ******* *******, ********** ******, *******, ********* ******, ***** (***) ***
****** ********* ***** ********* ***************, ***. *********** ***** *** ******, ****** *********, ********** (**) *****, ****** ****** (***) ***
****** ****** ****** *************** ******* ******* *********** **** ** ** & **, ******* ******* ******** **** *******-***** *.*. **. **, ***.: ******, ***.: ******, *********, ** ******, ***** (***) ***
****** ******* ****-****** ******* ****-****** *********** ************** **.,***. (*** ****) *********** **, ** ***** ****, ******* **** *** *** ********** *********** **** ******* ******, *******, ******* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.